Prelude Therapeutics, Inc. (PRLD) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Prelude Therapeutics, Inc. faces significant legal and financial risks due to potential liabilities under the U.S. Foreign Corrupt Practices Act and Chinese anti-corruption law. The company’s dealings in mainland China, and activities in Taiwan, may lead to exposure from corrupt actions by employees, consultants, or agents beyond its control. Despite current compliance efforts, any failure in safeguarding against corruption could result in harsh penalties, impacting Prelude Therapeutics’ business and financial stability. Additionally, the firm could be held accountable for misconduct by acquired entities, compounding its risk exposure.
Overall, Wall Street has a Moderate Buy consensus rating on PRLD stock based on 1 Buy and 2 Holds.
To learn more about Prelude Therapeutics, Inc.’s risk factors, click here.
